2. Signaling Pathways
  3. Autophagy
  4. LRRK2

LRRK2

Leucine-rich repeat kinase 2

LRRK2

Related Products

PDF 0.12 MB

Leucine-rich repeat kinase 2 (LRRK2) is a ubiquitously expressed member of the ROCO protein family. LRRK2 is a complex, multidomain protein containing kinase and GTPase enzymatic activities and multiple protein-protein interaction domains. LRRK2 is the genetic cause of both familial and idiopathic Parkinson's disease (PD), and it is associated with neuronal death, vesicle trafficking, mitochondrial dysfunction, and inflammation.

LRRK2 is a very large protein comprised of 2527 amino acids which has been determined to contain multiple functional domains, including armadillo (ARM), ankyrin-repeats (ANK), leucine-rich repeats (LRR), Ras of complex proteins (ROC), C-terminal of Roc (COR), MAPK-like kinase, and WD40 motifs. Mutations in LRRK2 represent a significant component of both sporadic and familial PD. Pathogenic mutations cluster in the enzymatic domains of LRRK2, and kinase activity seems to correlate with cytotoxicity, suggesting the possibility of kinase-based therapeutic strategies for LRRK2-associated PD. The best-characterized mutation to date, G2019S, leads to increased kinase activity, and mutations in the GTPase domain, such as R1441C and R1441G, have also been reported to influence kinase activity.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-174420
    RN277
    		Inhibitor
    RN277 is an inhibitor for LRRK2 type II kinase. RN277 can be used as a cellular tool targeting the LRRK2 inactive state. RN277 can inhibit LRRK1 kinase activity in vitro. RN277 inhibits LRRK2 kinase activity in vitro (IC50 = 70 nM). RN277 reduces phosphorylation of Rab8a dose-dependently. RN277 can be studied in research for Parkingson’s disease.
    RN277
  • HY-178796
    PROTAC LRRK2 Degrader-4
    		Degrader
    PROTAC LRRK2 Degrader-4 is a PROTAC LRRK2 degrader with a DC50 of 0.79 nM. PROTAC LRRK2 Degrader-4 can be used for research in Parkinson’s disease and inflammation.
    PROTAC LRRK2 Degrader-4
  • HY-158365
    LRRK2-IN-14
    		Inhibitor
    LRRK2-IN-14 (Compound 8) is an orally active LRRK2 inhibitor. LRRK2-IN-14 has an IC50 of 6.3 nM for LRRK2(G2019S) cell activity.LRRK2-IN-14 has an inhibitory effect on hERG (IC50=22 μM). LRRK2-IN-14 has blood-brain barrier permeability.
    LRRK2-IN-14
  • HY-153103
    LRRK2/NUAK1/TYK2-IN-1
    		Inhibitor
    LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), TYK2 and NUAK1, with IC50 values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research.
    LRRK2/NUAK1/TYK2-IN-1
  • HY-174427
    RN341
    		Inhibitor
    RN341 is a specific type II kinase inhibitor of LRRK2 (IC50: 296 nM). RN341 inhibits LRRK2 phosphorylation and avoids S935 dephosphorylation by stabilizing the open conformation. RN341 rescues LRRK2-mediated kinesin motility block by preventing microtubule binding. RN341 effectively inhibits LRRK2 wild-type and G2019S mutant at the cellular level. RN341 provides a new direction for Parkinson's disease research.
    RN341
  • HY-151444
    LRRK2-IN-6
    		Inhibitor
    LRRK2-IN-6 (compound 22) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 4.6 and 49 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-6 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-6 can cross the blood-brain barrier.
    LRRK2-IN-6
  • HY-165543
    SRI-29132
    		Inhibitor
    SRI-29132 is a potent leucine-rich repeat kinase 2 (LRRK2) inhibitor. SRI-29132 is promising for research of Parkinson’s disease.
    SRI-29132
  • HY-178797
    PROTAC LRRK2 Degrader-3
    		Degrader
    PROTAC LRRK2 Degrader-3 (compound 6) is a PROTAC LRRK2 degrader with a DC50 of 0.17 nM. PROTAC LRRK2 Degrader-3 can be used for research in Parkinson’s disease and inflammation.
    PROTAC LRRK2 Degrader-3
  • HY-175651
    LRRK2-IN-20
    		Inhibitor
    LRRK2-IN-20 (EX. 4.64) is a LRRK2 inhibitor with a pIC50 of 0.7921 nM. LRRK2-IN-20 can be used in Parkinson's disease (PD) research.
    LRRK2-IN-20
  • HY-144074
    LRRK2-IN-4
    		Inhibitor
    LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC50 of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease.
    LRRK2-IN-4
  • HY-177016
    LRRK2-IN-19
    		Inhibitor
    LRRK2-IN-19 is a PROTAC target protein ligand that can be used to synthesize PROTAC JH-XII-03-02 (HY-155150). JH-XII-03-02 is a highly potent and selective LRRK2 PROTAC degrader, which can be used in Parkinson's disease research.
    LRRK2-IN-19
  • HY-151441
    LRRK2-IN-5
    		Inhibitor
    LRRK2-IN-5 (compound 25) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 1.2 and 16 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-5 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-5 can cross the blood-brain barrier.
    LRRK2-IN-5
  • HY-134562
    PF-06371900
    		Inhibitor 99.43%
    PF-06371900 is a potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor.
    PF-06371900
  • HY-168041
    LRRK2-IN-15
    		Inhibitor
    LRRK2-IN-15 is an LRRK2 inhibitor. The IC50 value for PBMC cells is 5 nM, and the IC50 value for BCRP is 1.5 μM. LRRK2-IN-15 can be used for research on Parkinson's disease.
    LRRK2-IN-15
  • HY-162699
    LY2023-001
    		Inhibitor
    LY2023-001 is a potent G2019S LRRK2 inhibitor with an IC50 of 12.9 nM. LY2023-001 formed stable hydrogen bonds with Glu1948, and Ala1950 in the G2019S LRRK2 protein.
    LY2023-001
  • HY-161571
    LRRK2-IN-13
    		Inhibitor
    LRRK2-IN-13 (Compound 13) is an inhibitor of LRRK2 (IC50=0.57 nM). LRRK2-IN-13 has brain penetrating properties.
    LRRK2-IN-13
  • HY-182928
    LRRK2-IN-21
    		Inhibitor
    LRRK2-IN-21 is a selective, blood-brain barrier-permeable LRRK2 kinase inhibitor with an IC50 of 0.35 nM. LRRK2-IN-21 inhibits TTK kinase with an IC50 of 70 nM. LRRK2-IN-21 is applicable to the research of Parkinson's disease.
    LRRK2-IN-21
  • HY-161570
    LRRK2-IN-12
    		Inhibitor
    LRRK2-IN-12 (compound 1) inhibits the activity of LRRK2 G20195 (IC50=0.45 nM), LRRK2 WT (IC50=1.1 nM) and LRRK2 WT ADP-Glo (IC50=0.46 nM). LRRK2-IN-12 can be used for Alzheimer's Disease research.
    LRRK2-IN-12
  • HY-171802
    PROTAC LRRK2 Degrader-2
    		Degrader
    PROTAC LRRK2 Degrader-2 is a PROTAC-based degrader targeting LRRK2 with a DC50 of 0.14 nM. PROTAC LRRK2 Degrader-2 recruits LRRK2 or its mutants to the cereblon E3 ubiquitin ligase, thereby mediating the targeted ubiquitination and subsequent proteasomal degradation of LRRK2. PROTAC LRRK2 Degrader-2 can be used in research related to Parkinson's disease.
    PROTAC LRRK2 Degrader-2
  • HY-40294R
    Indazole (Standard)
    		Inhibitor
    Indazole (Standard) is the analytical standard of Indazole. This product is intended for research and analytical applications. Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases.
    Indazole (Standard)
Cat. No. Product Name / Synonyms Application Reactivity